COMMUNIQUÉS West-GlobeNewswire

-
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14/09/2024 -
KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
14/09/2024 -
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
14/09/2024 -
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
14/09/2024 -
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
14/09/2024 -
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14/09/2024 -
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14/09/2024 -
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
14/09/2024 -
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
14/09/2024 -
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
14/09/2024 -
Company Statement on FDA Advisory Committee Meeting
14/09/2024 -
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
14/09/2024 -
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
13/09/2024 -
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/09/2024 -
KKR to Purchase of 11,619,998 Shares of BrightSpring Health Services Common Stock from Walgreens Boots Alliance
13/09/2024 -
Fagron completes share buy-back program
13/09/2024 -
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
13/09/2024 -
Virbac : Rapport financier semestriel 2024
13/09/2024 -
Virbac : Half-yearly financial report 2024
13/09/2024
Pages